2012 - Europe Direct Iasi

EUROINVENT 2012
Patent no. MD 2003
The invention relates to a group of new tiosemicarbazona class
of coordination compounds of transition metals, biologically
active, showing marked bactericidal activity against grampositive
and gram-negative bacteria and fungicides. The activity
of compounds is much higher compared with furacilini and
nistatini used in medical practice. Antibacterial activity is higher
by 64-4166 times the gram-positive microorganisms and from 2
Description
to 297 times the gram-negative microorganisms, compared with
furacilini and antifungal activity is 1,6 to 25,8 times higher
compared with nistatini. However, the toxicity of compounds
present is about 8 times lower compared with furacilini toxicity.
The procedure for obtaining the compounds is simply declared,
the initial substances are available, environmentally safe yield is
82%. Application: Medical and veterinary. Pharmaceutical
industry.
4.30.
Title Remedies new antiviral treatment and prophylaxis of oral herpes.
Authors Diana Uncuţa, Valeriu Rudic
Institution
State Medical
Testemiţanu”
and Pharmaceutical University „Nicolae
Patent no.
MD 4110, 3724, 2671; Application MD: a20100032, a20100033,
Description
a20100034
Advantages drug used to treat oral herpes diseases consist
curative effect manifested major antiviral properties,
inflammatory, regenerative. Drug use through effective drug to
reduce the occurrence of relapses during treatment preventing
these viral illnesses.
4.31.
Title
PROCEDURE FOR THE PROGNOSIS OF THYROID
CANCER PROGRESSION RISK
Authors Victor Popescu
Institution
State Medical
Testemiţanu”
and Pharmaceutical University „Nicolae
Patent no. MD - 4038
Description
Invention provides identification of the methylation profiles of
p15 gene in the DNA extracted from malignant tumor fragments
of the thyroid gland and their comparison with the profiles of
normal peritumoral tissue.
Class 4
88